2006 Industry Dynamics: Lessons to Be Learned : Market Research Report

2006 Industry Dynamics: Lessons to Be Learned

Published: Dec. 21, 2006 - 35 Pages

Price reduced due to age.

Executive Summary: Strategic Considerations
Stakeholder Implications: 2006 in Review
2006’s Winning Technology: Worldwide Sales and Blockbusters
2006 MAb Approvals: Big Pharma’s Frenzied Acquisition of MAb Companies
Disaster Strikes Tysabri: Sarah W. Fuller, Andrea S. Witt, Ph.D., Decision Resources
The Silver Lining: Generics’ Bloody Battlefield
Authorized Generics: At-Risk Launch of Generics
Paul King, M.S., J.D., Member of the District of Columbia Bar, KING PLLC, Capitol Hill: World’s Largest Generics Company
Paul King, M.S., J.D., Member of the District of Columbia Bar, KING PLLC, Capitol Hill: Consolidation Woes
Serial Consolidation in Big Pharma: Barrie G. James, Ph.D., Pharma Strategy Consulting
European Midsize Pharma—End of the Beginning or Beginning of the End?: Barrie G. James, Ph.D., Pharma Strategy Consulting
Generics Companies—Bulking Up in 2006: Pfizer Burns
Four Major Announcements in Five Days: Radical Changes at Pfizer—R&D Emphasis Still Out of Touch with Reality
John Ansell, M.A., John Ansell Consultancy: Two Years of Frustrating Productivity
Problems of Size: Nose-Diving Productivity
Rise and Fall of Combination Products: 2006’s Major Battle for Dominance in Stent Markets
2006 Crisis—Thrombosis Linked to Drug-Eluting Stents: Outlook
Appendix
Figures: 1. MAbs: From Mouse to Human; 2. $13 Billion Monoclonal Antibody Sales, First 3 Quarters of 2006; 3. Tysabri 2004-2006 Timeline; 4. Dollar Value of Branded Drugs Going Off-Patent, 1995-2010; 5. Receipts of Original Abbreviated New Drug Applications (ANDAs), 2001-2006; 6. Top 1984 Pharmaceutical Companies Compared with Top 2004 Generics Companies; 7. Serial Consolidation in the Pharmaceutical Industry; 8. Market Capitalization of Select Companies, December 8, 2006; 9. Drug-Eluting Stents; 10. Worldwide Sales Comparisons: Boston Scientific’s Taxus Stent vs. Cordis/ Johnson & Johnson’s Cypher Stent
Tables: 1. Prices of Select Cancer Therapies in the United States, 2001-2005; 2. Branded Drugs Authorized as Generics in 2006; 3. Generics Companies Bulk Up, 2006; 4. Select Pfizer Deals, January to November 2006

Abstract

Stunning successes and startling failures highlight 2006’s pharmaceutical industry. In this year-end retrospective report, we contemplate the importance of these developments and what they mean to the pharmaceutical industry. Additionaly, we asked industry experts for their opinions and integrated their commentary and analysis into this report.

Get the Answers You Need to Shape Your Strategy
The winning technology of 2006 continues to be a major success for the drug industry; however, even successful and well-tried innovations can meet with disaster. Which technology has Decision Resources deemed most lucrative in 2006, and why is its potential for commercial success so great? Which particular agent proves that even the most promising technologies are not immune to the risks inherent in development?

2006 saw more development and deals within a group of products that is poised to dramatically change the way diseases are currently treated. What is this group of products, and what were the major business strategies and deals within this group in 2006?

Competition between innovator companies and generics companies has never been higher as these groups battle to control drug markets; innovator companies continue to face unrelenting pressure from generics companies that want to invalidate drug patents and gain early market entry for their drugs. What were 2006’s developments on the generics front line? What strategies are innovator companies employing to ward off generics competition? A prominent strategy of the pharmaceutical industry—historically employed to bolster thin product pipelines and increase presence in more markets—continues in 2006. However, this strategy is threatening the productivity and innovation of the largest pharmaceutical manufacturers. What longstanding practice in the pharmaceutical industry is counterproductive in today’s industry? How may the recent decisions of one major company serve as a lesson?

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2006 Industry Dynamics: Lessons to Be Learned

Table of Contents

Abstract